- Home
- INTC vs AZN Comparison
INTC vs AZN Comparison
Compare INTC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTC | AZN |
|---|---|---|
| Founded | 1968 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.1B | 283.9B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | INTC | AZN |
|---|---|---|
| Price | $45.16 | $92.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 32 | 2 |
| Target Price | ★ $39.42 | N/A |
| AVG Volume (30 Days) | ★ 109.3M | 8.2M |
| Earning Date | 01-22-2026 | 02-10-2026 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | N/A | ★ 45.02 |
| EPS | N/A | ★ 6.02 |
| Revenue | $52,853,000,000.00 | ★ $58,127,000,000.00 |
| Revenue This Year | $3.47 | $11.40 |
| Revenue Next Year | $5.24 | $6.06 |
| P/E Ratio | ★ N/A | $15.23 |
| Revenue Growth | N/A | ★ 13.52 |
| 52 Week Low | $17.67 | $61.24 |
| 52 Week High | $54.60 | $96.51 |
Technical Indicators
Market Signals| Indicator | INTC | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 51.78 |
| Support Level | $46.71 | $89.04 |
| Resistance Level | $54.60 | $96.43 |
| Average True Range (ATR) | 2.85 | 1.83 |
| MACD | 0.61 | -0.40 |
| Stochastic Oscillator | 39.33 | 51.27 |
Price Performance
Historical ComparisonAbout INTC Intel Corporation
Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and led the semiconductor industry down the path of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel is seeking to reinvigorate its chip manufacturing business, Intel Foundry, while developing leading-edge products within its Intel Products business segment.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.